Abstract:Signal transducer and activator of transcription 3 (STAT3) is constitutively activated in malignant tumors and has important roles in multiple aspects of cancer aggressiveness. Thus targeting STAT3 promises to be an attractive strategy for treatment of advanced metastatic tumors. Although many STAT3 inhibitors targeting the SH2 domain have been reported, few have moved into clinical trials. Targeting the DNA-binding domain (DBD) of STAT3, however, has been avoided due to its 'undruggable' nature and potentially limited selectivity. In a previous study, we reported an improved in silico approach targeting the DBD of STAT3 that resulted in a small-molecule STAT3 inhibitor (inS3-54). Further studies, however, showed that inS3-54 has off-target effect although it is selective to STAT3 over STAT1. In this study, we describe an extensive structure and activity-guided hit optimization and mechanistic characterization effort, which led to identification of an improved lead compound (inS3-54A18) with increased specificity and pharmacological properties. InS3-54A18 not only binds directly to the DBD and inhibits the DNA-binding activity of STAT3 both in vitro and in situ but also effectively inhibits the constitutive and interleukin-6-stimulated expression of STAT3 downstream target genes. InS3-54A18 is completely soluble in an oral formulation and effectively inhibits lung xenograft tumor growth and metastasis with little adverse effect on animals. Thus inS3-54A18 may serve as a potential candidate for further development as anticancer therapeutics targeting the DBD of human STAT3 and DBD of transcription factors may not be 'undruggable' as previously thought.

Discovery of Novel Inhibitors of Signal Transducer and Activator of Transcription 3 (STAT3) Signaling Pathway by Virtual Screening

Identification and Characterization of Small Molecule Inhibitors of Signal Transducer and Activator of Transcription 3 (STAT3) Signaling Pathway by Virtual Screening.

Discovery, Synthesis, and Evaluation of Small-Molecule Signal Transducer and Activator of Transcription 3 Inhibitors

Design, Synthesis and Biological Evaluation of Small-Molecule Inhibitors of Signal Transducer and Activator of Transcription 3 (stat3) Signaling Pathway

Design, Synthesis and Biological Evaluation of Benzyloxyphenyl-Methylaminophenol Derivatives As STAT3 Signaling Pathway Inhibitors.

Structure-based Discovery of Potent and Selective Small-Molecule Inhibitors Targeting Signal Transducer and Activator of Transcription 3 (STAT3).

Discovery, Optimization, and Evaluation of Novel N -(Benzimidazol-5-yl)-1,3,4-thiadiazol-2-amine Analogues as Potent STAT3 Inhibitors for Cancer Treatment

Design, Synthesis and Evaluation of Quinoline-based Small Molecule Inhibitor of STAT3

Discovery of potent STAT3 inhibitors using structure-based virtual screening, molecular dynamic simulation, and biological evaluation

Discovery of New Benzensulfonamide Derivatives As Tripedal STAT3 Inhibitors.

Novel 2-Carbonylbenzo[b]thiophene 1,1-Dioxide Derivatives as Potent Inhibitors of STAT3 Signaling Pathway.

A Low-Molecular-weight Compound Discovered Through Virtual Database Screening Inhibits Stat3 Function in Breast Cancer Cells.

Discovery of Novel STAT3 Small Molecule Inhibitors Via in Silico Site-Directed Fragment-Based Drug Design.

Discovery of an Orally Selective Inhibitor of Signal Transducer and Activator of Transcription 3 Using Advanced Multiple Ligand Simultaneous Docking

Rational drug design of benzothiazole-based derivatives as potent signal transducer and activator of transcription 3 (STAT3) signaling pathway inhibitors

Antagonizing STAT3 Activation with Benzo[b]thiophene 1, 1-Dioxide Based Small Molecules.

Benzobis(imidazole) derivatives as STAT3 signal inhibitors with antitumor activity

Novel STAT3 Inhibitors Targeting STAT3 Dimerization by Binding to the STAT3 SH2 Domain

Small Molecule Inhibitors of Il-6/Stat3 Signaling

Small-molecule Inhibitors Targeting the DNA-binding Domain of STAT3 Suppress Tumor Growth, Metastasis and STAT3 Target Gene Expression in Vivo

Identification of novel STAT3 inhibitors bearing 2-acetyl-7-phenylamino benzofuran scaffold for antitumour study